| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
Bemotrizinol targets UV radiation by absorbing UVB and UVA rays. The compound's chemical structure allows it to absorb UV radiation and convert it to harmless heat energy, preventing it from reaching the skin. As a broad-spectrum UV filter, it protects the skin from UV-induced damage including sunburn, photoaging, and skin cancer. Its targets are physical (UV radiation) rather than biological.
|
|---|---|
| ln Vitro |
Bemotrizinol absorbs UVB (280-320 nm) and UVA (320-400 nm) radiation in vitro, providing broad-spectrum photoprotection. The compound is photostable and does not degrade significantly upon exposure to sunlight. These in vitro findings support its applications in sunscreen and cosmetic products.
|
| ln Vivo |
Bemotrizinol is used in sunscreen and cosmetic products for topical application. The compound provides broad-spectrum UV protection when applied to the skin, preventing UV-induced damage including sunburn, photoaging, and skin cancer. Its photostability ensures long-lasting protection. The compound has been approved for use in sunscreens in many countries worldwide.
|
| Enzyme Assay |
In vitro UV absorption assays for Bemotrizinol typically involve measuring its absorption spectrum using UV-Vis spectroscopy. The compound's absorbance in the UVB (280-320 nm) and UVA (320-400 nm) ranges is measured. Photostability is assessed by exposing the compound to UV radiation and monitoring changes in absorbance over time. The compound's purity and identity are confirmed using analytical chemistry methods such as high-performance liquid chromatography and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Bemotrizinol involve culturing skin cells to evaluate its photoprotective effects. Cells are treated with the compound and exposed to UV radiation; cell viability and DNA damage are assessed. The compound's ability to prevent UV-induced oxidative stress is evaluated by measuring reactive oxygen species levels. All experiments are performed with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Bemotrizinol have been conducted to evaluate its photoprotective efficacy and safety. Animals are treated with the compound and exposed to UV radiation; skin damage is assessed. Parameters assessed include erythema, edema, skin histopathology, and DNA damage. The compound's safety and efficacy have been demonstrated in various studies. Control groups receiving vehicle alone are included for comparison.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Pharmacokinetic data are unavailable. Absorption, Distribution and Excretion ... The pharmacokinetic properties of Bemotrizinol reflect its nature as a topical UV filter. It has a molecular weight of 462.58 and the molecular formula C28H34N2O4. The compound is designed for topical application and is minimally absorbed through the skin. When absorbed, it is metabolized through standard xenobiotic pathways and excreted. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies. |
| Toxicity/Toxicokinetics |
Protein Binding
No pharmacokinetic data available. The toxicity profile of Bemotrizinol has been extensively evaluated for its use in sunscreen and cosmetic products. The compound is generally recognized as safe for topical use at concentrations up to 10%. It has low skin penetration and low systemic absorption, minimizing potential systemic toxicity. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is approved for use in sunscreens in many countries. |
| References |
[1]. Durán-Giner N, et al. Solar filters as feasible acceptors of atomic oxygen. Photochem Photobiol Sci. 2013;12(5):725-728.
|
| Additional Infomation |
Bemotrizinol belongs to the methoxybenzene class of compounds. Bemotrizinol, also known as bis-ethylhexyloxyphenol methoxyphenyl triazine, is an organic ultraviolet filter commonly found in over-the-counter sunscreens. It primarily absorbs UVA rays. Compared to traditional broad-spectrum chemical sunscreens, bemotrizinol has higher lipid solubility (easily soluble in cosmetic oils), thus enhancing its efficacy and broad-spectrum sun protection. It is claimed to have photostability, which improves its onset of action and enhances the protective effect against ultraviolet rays after topical application. Common brand names for bemotrizinol include Tinosorb S and Escalol S. Pharmacological Indications: Used as an active sunscreen agent. Mechanism of Action: Bemotrizinol prevents the generation of ultraviolet radiation-induced free radicals by absorbing UVA and UVB rays in the wavelength range of 280 to 400 nanometers.
Pharmacodynamics Results of a competitive binding assay of uterine nutrients in immature rats showed that bemotrazazole has no significant binding affinity for estrogen and androgen receptors in vitro, thus lacking intrinsic estrogenic, anti-estrogenic, androgenic, and anti-androgenic activities. Bemotrazazole can maximally reduce erythema and has excellent anti-aging effects as well as protective effects on the skin's antioxidant defense system. In a comparative study of photoexcitation tests in individuals with a history of polymorphic light eruption (PLE), bemotrazazole treatment effectively prevented the occurrence of PLE. Bemotrizinol (CAS# 187393-00-6) is also known as Tinosorb S. It has the molecular formula C28H34N2O4 and a molecular weight of 462.58. The compound is a broad-spectrum UV filter that absorbs both UVB (280-320 nm) and UVA (320-400 nm) radiation. It is photostable and widely used in sunscreen and cosmetic products worldwide. |
| Molecular Formula |
C38H49N3O5
|
|---|---|
| Molecular Weight |
627.81
|
| Exact Mass |
627.367
|
| CAS # |
187393-00-6
|
| PubChem CID |
135487856
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
782.0±70.0 °C at 760 mmHg
|
| Melting Point |
83-85°; mp 80° (Mongiat)
|
| Flash Point |
426.7±35.7 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
13.89
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
46
|
| Complexity |
761
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1C([H])=C([H])C(C2N=C(C3C([H])=C([H])C(=C([H])C=3[H])OC([H])([H])[H])N=C(C3C([H])=C([H])C(=C([H])C=3O[H])OC([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])N=2)=C(C=1[H])O[H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
XVAMCHGMPYWHNL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C38H49N3O5/c1-6-10-12-26(8-3)24-45-30-18-20-32(34(42)22-30)37-39-36(28-14-16-29(44-5)17-15-28)40-38(41-37)33-21-19-31(23-35(33)43)46-25-27(9-4)13-11-7-2/h14-23,26-27,42-43H,6-13,24-25H2,1-5H3
|
| Chemical Name |
5-(2-ethylhexoxy)-2-[4-[4-(2-ethylhexoxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazin-2-yl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5928 mL | 7.9642 mL | 15.9284 mL | |
| 5 mM | 0.3186 mL | 1.5928 mL | 3.1857 mL | |
| 10 mM | 0.1593 mL | 0.7964 mL | 1.5928 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT05277376
Conditions:Pharmacokinetics|Absorption; ChemicalsLink: https://clinicaltrials.gov/ct2/show/NCT04355286
Conditions:Absorption; Chemicals|Sunscreening AgentsProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
